| Scorecard |
|---|
|
4 / 5 Stars
|
|
Lipper
5
5
5
5
3
|
|
Zacks Investment Research
1
(Strong Buy)
|
|
Standard & Poor's
5 / 5 Stars
|
|
TheStreet.com
A+
(Buy)
|
#5 in Large Blend
U.S. News evaluated 496 Large Blend Funds. Our list highlights the top-rated funds for long-term investors based on the ratings of leading fund industry researchers.
Performance
The fund has returned 30.50 percent over the past year, 15.89 percent over the past three years, and 7.11 percent over the past five years.
| Trailing Returns | Updated 05.31.2013 |
|---|---|
| Year to date | 17.6% |
| 1 Year | 30.5% |
| 3 Years (Annualized) | 15.9% |
| 5 Years (Annualized) | 7.1% |
| 10 Years (Annualized) | N/A |
Summary
With only about $300 million total assets under management, this fund is the smallest of the six funds managed by Primecap. A small asset base generally makes it easier for the fund to move in and out of positions. It also boasts a low turnover rate. As of the end of December 2009, the fund is invested in about 90 stocks. Almost a third of the fund’s total assets are in the healthcare sector in names like Eli Lilly, Roche and Amgen.
Investment Strategy
The investment seeks to provide long-term capital appreciation. The fund invests primarily in the common stocks of U.S. companies. It invests at least 80% of its assets in stocks. The fund may invest in stocks across all market sectors and market capitalizations, though it has historically invested primarily in large- and mid-capitalization companies.
Fees
Fees are Above Average compared to funds in the same category.
PrimeCap Odyssey Stock Fund has an expense ratio of 0.66 percent.
Risk
Risk is Below Average compared to funds in the same category according to Morningstar.
